|
|
Post by roseylv on Oct 18, 2017 16:15:44 GMT -5
this Euro Patent does nothing for us in the short term. Especially in a country that is not even, so called "targeted". Of course it's always best to protect your main asset but it's was not even a PR worthy update.
Onward!
|
|
|
|
Post by lakers on Oct 18, 2017 20:04:04 GMT -5
3:04 PM 10/18/2017 - MT Newswires
03:04 PM EDT, 10/18/2017 (MT Newswires) -- The European Patent Office on Wednesday granted MannKind (MNKD) its patent for dry powder inhalers, cartridges for dry powder inhalers and a system for rapid drug delivery to the pulmonary tract, including dry powders comprising active agents for the treatment of disease, including diabetes and obesity, according to the patent office annoucement. Still, MannKind shares were down more than 9% at $4.32 in late trade. The stock hit a 52-week high of $6.96 early this month, but has since faltered following its 10.2 million shares sale at $6 apiece to raise $61 million.Price: 4.31, Change: -0.45, Percent Change: -9.37
|
|
|
|
Post by seanismorris on Oct 18, 2017 20:44:31 GMT -5
I kind of assumed that Afrezza was well protected, patent wise, in the EU.
I don’t know if this was the ‘international news’ that we were expecting, but if it is, my response is:
Meh...
I don’t think the market action today (down) was a response to this.
|
|
|
|
Post by patten1962 on Oct 18, 2017 21:08:05 GMT -5
Anyone have a guess if this helps stock price tomorrow?
|
|
|
|
Post by seanismorris on Oct 18, 2017 21:25:20 GMT -5
Anyone have a guess if this helps stock price tomorrow? I doubt it. Our hope is Fridays scripts looks decent enough to stop the slide. |
|
|
|
Post by mydogskip on Oct 19, 2017 3:46:13 GMT -5
Anyone have a guess if this helps stock price tomorrow? I doubt it. Our hope is Fridays scripts looks decent enough to stop the slide. Don't hold your breath on that drastic script increase coming to fruition. The MNKD stock manipulation is in effect. I am surprised the SEC isn't looking into it. |
|
|
|
Post by mydogskip on Oct 19, 2017 3:54:33 GMT -5
Patents are dime a dozen 😜 Negative. No, he's right. If MNKD's patents meant anything, the company would be worth a whole lot more than what it is now. Patents only have value when they protect something that actually has value. Right now, nothing Mannkind has has any significant value. Wall Street still has the opinion that Mannkind is living on borrowed time and will fail. That's been their narrative for years now. Us investors in Mannkind ~yes I have a small stake ~ have been waiting for ever for the company to blossom. But good drugs with bad management is a recipe for disaster. That's been the case for Mannkind for a long time. Castagna is a vast improvement over the past management of the company, including Al in his later years. Mike might just be able to save the company and allow Afrezza to become a profitable niche drug for diabetics while making money for its investors. Time will tell but even with the small capital infusion, time is running out. |
|
|
|
Post by mnholdem on Oct 19, 2017 11:33:12 GMT -5
I doubt it. Our hope is Fridays scripts looks decent enough to stop the slide. Don't hold your breath on that drastic script increase coming to fruition. The MNKD stock manipulation is in effect. I am surprised the SEC isn't looking into it. Goldman Sachs Group Inc., JPMorgan Chase & Co. and four other investment banks are conspiring to control the more than $1 trillion market for lending stocks, according to a federal lawsuit.
The complaint by the Iowa Public Employees Retirement System and two other pension plans claims the banks are blocking a shift to all-electronic system for matching lenders and borrowers of shares, so they can continue to profit from each transaction. In a short sale, traders sell borrowed stock, anticipating the price will drop so they can profit by buying back the shares at a lower price.
“Major investment banks are conspiring to preserve their profits at the expense of everyday investors,” plaintiffs’ attorney Michael Eisenkraft of Washington-based Cohen Milstein Sellers & Toll said in a statement Thursday. The investors are seeking unspecified damages in the class-action antitrust case, which could be tripled under federal law.
The lawsuit is the most recent to accuse the world’s biggest banks of manipulating the markets in which they operate. In other cases, lenders have paid billions of dollars in penalties to U.S. authorities for rigging benchmark interest rates, foreign-currency transactions and municipal-bond investment contracts.
In the new suit, the banks allegedly stifled a shift to an electronic “all-to-all” market that would enhance price transparency and competition, while eliminating them as transactional middle men. The market for lending stocks plays a vital role in the U.S. economy, allowing hedging while also ensuring that financial systems operate efficiently.
---
Defendants in the suit also include Bank of America Corp., Morgan Stanley, Credit Suisse Group AG, and UBS AG. Representatives of all the banks declined to comment.
Source: www.bloomberg.com/news/articles/2017-08-17/bofa-goldman-sued-in-securities-lending-market-antitrust-case
---
It's my understanding that a corporation has access to all data related to their stock transactions. Could MannKind identify the individuals/firms involved in illegal naked-short (counterfeit) trading? Could MNKD shareholders launch a lawsuit against them?
I wish we shareholders could sue the SEC, but they are protected by federal law.
|
|
|
|
Post by centralcoastinvestor on Oct 19, 2017 11:44:09 GMT -5
Great find. This is a good write up to counter all of those naysayers, even on this board, that refuse to believe that there is short manipulation. At some point, when MannKind is healthier financially, I think they should legally go after the brokerages, market makers and individuals that have cheated its shareholders.
|
|
|
|
Post by sportsrancho on Oct 19, 2017 12:22:59 GMT -5
@natesnotes
10/19/17, 10:12 AM
@proximacentaurib they really don't seem to realize what a large torpedo that European patent may turn out to be re: their $MNKD short :-)
|
|
|
|
Post by dreamboatcruise on Oct 19, 2017 13:20:00 GMT -5
Great find. This is a good write up to counter all of those naysayers, even on this board, that refuse to believe that there is short manipulation. At some point, when MannKind is healthier financially, I think they should legally go after the brokerages, market makers and individuals that have cheated its shareholders. Actually this article has nothing to do with short manipulation of the underlying stock. It is about the brokers/banks overcharging shorters on interest or underpaying those of us that lend. It's interesting you read it and see in it some noion of short manipulation. I guess that is a form of confirmation bias. Personally I believe shorts and longs manipulate this stock, and there are likely many that play both sides. That creates short term volatility and over sized swings. |
|
|
|
Post by mango on Oct 19, 2017 13:26:56 GMT -5
No, he's right. If MNKD's patents meant anything, the company would be worth a whole lot more than what it is now. Patents only have value when they protect something that actually has value. Right now, nothing Mannkind has has any significant value. Wall Street still has the opinion that Mannkind is living on borrowed time and will fail. That's been their narrative for years now. Us investors in Mannkind ~yes I have a small stake ~ have been waiting for ever for the company to blossom. But good drugs with bad management is a recipe for disaster. That's been the case for Mannkind for a long time. Castagna is a vast improvement over the past management of the company, including Al in his later years. Mike might just be able to save the company and allow Afrezza to become a profitable niche drug for diabetics while making money for its investors. Time will tell but even with the small capital infusion, time is running out. Your opinion is fine and all but is entirely inaccurate and untrue. There is a great video on YouTube with the speaker being from a company that was spun out from the AMI at the Technion I believe. Al and Claude are present in the audience and the speaker, the CEO of this company, describes exactly why patents protect the future and if done right, which is also the case with MannKind, ensures a future that obsoletes current therapies and technologies because they saw the future and were visionaries. Patents are everything in this game. |
|
|
|
Post by dreamboatcruise on Oct 19, 2017 13:28:47 GMT -5
Anyone have a guess if this helps stock price tomorrow? It's easier to guess now, but for future reference I might suggest looking at the hundreds of other patents MNKD has been issued and whether they have ever had a noticeable effect on stock price. |
|
|
|
Post by centralcoastinvestor on Oct 19, 2017 13:32:50 GMT -5
Great find. This is a good write up to counter all of those naysayers, even on this board, that refuse to believe that there is short manipulation. At some point, when MannKind is healthier financially, I think they should legally go after the brokerages, market makers and individuals that have cheated its shareholders. Actually this article has nothing to do with short manipulation of the underlying stock. It is about the brokers/banks overcharging shorters on interest or underpaying those of us that lend. It's interesting you read it and see in it some noion of short manipulation. I guess that is a form of confirmation bias. Personally I believe shorts and longs manipulate this stock, and there are likely many that play both sides. That creates short term volatility and over sized swings. You are correct. I was wrong that the article proved short manipulation of the underlying stock. Thanks for holding me accountable on that. I need to read more carefully. It is interesting how the banks make fees on all those trades. So much is done behind the curtain that average investors will never know about. |
|
|
|
Post by compound26 on Oct 19, 2017 13:37:45 GMT -5
Anyone have a guess if this helps stock price tomorrow? It's easier to guess now, but for future reference I might suggest looking at the hundreds of other patents MNKD has been issued and whether they have ever had a noticeable effect on stock price. Agree. These patents generally have no impact on PPS. The reason is that these patent are generally filed quite a few years back. On these European patents I believe they were filed in 2009. So from that perspective, the date of granting a patent is generally a purely random date to the patent applicant (in this case, Mannkind). The point I am making is that the date of the granting of the patent is most likely not linked to any major event (like drug application filing, partnership announcement, etc.) in any way. However, that being said, the granting of a patent is always a positive development to me.  |
|
